v3.20.4
Consolidated Statement of Cash Flows - USD ($)
12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash flows from operating activities:    
Net loss $ (17,384,520) $ (26,132,130)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation 5,194,784 8,958,966
Research and development expense - license acquired CMU 0 1,046,965
Research and development expense - license acquired Ohr 0 11,920,450
Change in fair value of warrant liabilities 453,808 492,889
Depreciation and amortization 280,463 128,372
Loss on disposal of fixed asset 3,230 0
Equity in losses on equity method investment 262,861 0
Non-cash amortization on convertible notes 0 94,444
Non-cash interest expense on convertible notes 0 21,772
Changes in operating assets and liabilities    
Other prepaid expenses and current assets 264,442 (386,499)
Long-term prepaid insurance 193,666 (338,916)
Accounts payable (129,088) 962,434
Accrued expenses and other current liabilities 150,283 385,765
Net cash used in operating activities (10,710,071) (2,845,488)
Cash flows from investing activities    
Purchase of laboratory and office equipment (716,820) (455,200)
Cash acquired in connection with Acquisition of Ohr 0 752,419
Payment of transaction costs for Acquisition of Ohr 0 (884,981)
Payment of transaction costs for licenses acquired- CMU 0 (43,463)
Cash paid for license acquired 0 (54,000)
Net cash used in investing activities (716,820) (685,225)
Cash flows from financing activities    
Principal payment of financed insurance (349,792) (90,081)
Proceeds from issuance of stock, net of issuance costs 33,283,970 0
Proceeds from exercise of stock options 171,030 0
Proceeds from issuance of common stock in pre-acquisition financing, net of issuance costs 0 8,268,157
Proceeds from issuance of common stock in private placement financing, net of issuance costs 0 4,957,397
Proceeds from issuance of convertible notes 0 600,000
Payment for warrant redemption 0 (141,864)
Proceeds from issuance of common shares for services 0 1,474
Proceeds from prefunded warrant 0 10
Repurchase of common stock 0 (14)
Net cash provided by financing activities 33,105,208 13,595,079
Net increase in cash and cash equivalents 21,678,317 10,064,366
Cash and cash equivalents, beginning of period 10,313,966 249,600
Cash and cash equivalents, end of period 31,992,283 10,313,966
Supplemental disclosure of cash flow information:    
Cash paid for interest 3,244 3,177
Cash paid for income taxes 0 0
Non-cash investing and financing activities:    
Issuance of common stock for research and development expense-licenses acquired- CMU 0 844,600
Issuance of common stock and options for acquisition of Ohr 0 11,776,927
Fair value of warrant liability issued for research and development expense- licenses acquired 0 104,902
Issuance of common stock for conversion of debt 0 944,444
Issuance of common stock for conversion of accrued interest 0 21,772
Issuance of common stock for the cashless exercise of warrant 0 429,677
Insurance financed through note payable 365,430 213,000
Capital expenditures in accounts payable $ 156,978 $ 0

Source